1. Healthcare

  2. •

    Biotechnology
Tesaro, Inc.

Tesaro, Inc.

TSRO
Tesaro, Inc.US flagNASDAQ
74.96
USD
- -
- -
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.01
0.94
4.13
4.01
Basic EPS, GAAP
-1.72
-4.51
-2.93
-4.79
-6.38
-8.13
-9.17
-11.86
Free Cash Flow per Basic Share
-1.55
-3.72
-2.76
-4.01
-5.43
-6.5
-8.61
-10.48
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-6.36
-5.69
-9.81
-15.28
-20.79
-27.18
-35.4
Tangible Book Value per Share
-2.64
8.44
3.9
3.47
1.83
12.56
3.56
-3.05
Basic Weighted Avg Shares
10
14
32
36
39
48
54
55
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
45
223
219
Operating Margin (%)
- -
- -
- -
- -
-74,461.2
-827.59
-214.72
-283.27
Depreciation Expense
- -
- -
- -
- -
1
3
10
10
Net Income, GAAP
-16
-62
-92
-171
-251
-387
-496
-649
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-79,308.52
-864.45
-222.15
-295.67
Working Capital
39
115
122
234
190
738
622
458
LT Debt
- -
- -
- -
115
121
132
437
644
Total Equity
-25
116
123
124
87
611
249
-131
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
ST Debt
- -
- -
- -
LT Borrowings
440
640
644
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
55
55
Market Capitalization
3,103
2,425
2,134

Working Capital

FRC

•

in mil. unless spec.
Mar'18
Jun'18
Sep'18
Total Current Assets
656
757
648
Cash, Cash Equivalents & STI
499
575
477
Accounts Receivable, Net
44
36
31
Inventories
74
87
109
Total Current Liabilities
163
184
190
Payables & Accruals
156
172
179
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
104.31%
-59.25%
Free Cash Flow
- -
56.01%
50.49%
Net Income, GAAP
- -
52.77%
28.04%
Sales/Revenue/Turnover
- -
- -
398.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
37
4
4
45
2017
3
29
143
48
223
2018
50
57
64
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
-2.22
-1.28
-1.98
-2.6
-8.13
2017
-2.55
-2.82
-0.47
-3.35
-9.17
2018
-2.98
-3.04
-2.49
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -

Company Description

APIChatGPT
Sector
Healthcare
Industry
Biotechnology
Address
IPO Date
Jun 28, 2012
CIK
0001491576
Similar Companies
Promisia Healthcare Limited (PHL.NZ)
RenovoRx, Inc. (RNXT)
Aldeyra The (ALDX)
Anixa Biosciences, Inc. (ANIX)
Tharimmune, Inc. (THAR)
Lixte Biotechnology Holdings, Inc. (LIXTW)
Business
Tesaro Inc. (TSRO), a wholly owned subsidiary of GlaxoSmithKline plc since its $5.1 billion acquisition completed in January 2019, operates as an oncology-focused biopharmaceutical company headquartered in Waltham, Massachusetts, and founded in 2010. The company develops and commercializes cancer therapeutics and supportive care products, including Zejula (niraparib), an oral poly ADP-ribose polymerase (PARP) inhibitor approved for ovarian cancer maintenance therapy regardless of BRCA status; Varubi (rolapitant), an intravenous NK-1 receptor antagonist for chemotherapy-induced nausea and vomiting; and Jemperli (dostarlimab), a PD-1 inhibitor approved for mismatch repair deficient recurrent or advanced endometrial cancer following platinum-based therapy. Its pipeline features immuno-oncology assets such as antibodies targeting TIM-3, LAG-3, and additional PARP inhibitors like stenoparib, which received FDA Fast Track designation in 2025 for advanced indications; operations span North America, Europe, and clinical development in global markets. In recent developments, Tesaro initiated litigation in November 2025 against AnaptysBio Inc. in Delaware Chancery Court, alleging material breach of their 2014 collaboration agreement on Jemperli that could enable termination of the current license, acquisition of a perpetual license, and reduction of royalties and milestones by 50%; AnaptysBio countersued, escalating the dispute over contractual obligations. These legal actions represent the most significant recent operational changes for the GSK-integrated entity, amid ongoing advancements in its PARP inhibitor franchise and immuno-oncology portfolio.